



May 12, 2025

Company: KYORIN Pharmaceutical Co., Ltd.
Representative: Yutaka Ogihara
Representative Director, President and CEO
(Security Code: 4569, TSE Prime.)
Contact: Shota Kikuchi
Director, Corporate Planning
Telephone: 03-6374-9702

Notice Regarding Cancellation of Treasury Stock

KYORIN Pharmaceutical Co., Ltd. (the "Company") announced today that, at the Board of Directors meeting held on May 12, 2025, it has resolved to cancel its treasury shares pursuant to Article 178 of the Companies Act.

- | | |
|--------------------------------------|---|
| 1. Reason of cancellation: | Improve capital efficiency and shareholder returns |
| 2. Class of shares to be cancelled: | Common stock Company's common shares |
| 3. Number of shares to be cancelled: | 4,662,295 shares
(7.2% of the total number of issued shares before cancellation) |
| 4. Scheduled cancellation date: | May 30, 2025 |

(For reference)

The status of Company's shares after the cancellation of treasury shares is as follows,

The total number of issued shares: 59,945,641 shares

Number of the Company treasury shares: 1,800,000 shares*

(3.0% of the total number of issued shares after cancellation)

* The number of treasury shares after cancellation mentioned above does not include the 83,276 shares held in a trust account of the Custody Bank of Japan, Ltd. due to the introduction of the "Board Benefit Trust, BBT" and the 606,395 shares held in a trust account of the Custody Bank of Japan, Ltd. due to the introduction of the "Employee Stock Ownership Plan, J-ESOP."